Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | DDO | Q99489 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PNLIP | P16233 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12589315 | 0.85 | CA3 (0.46) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL2472494 | 0.83 | CA3 (0.43) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL438800 | 0.77 | ALDH1A1 (0.41) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL366147 | 0.76 | TSHR (0.54) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL593480 | 0.74 | SLC6A4 (0.39) | PTGS1HTR2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL337001 | 0.74 | SLC6A4 (0.42) | HTR2ANPC1MEN1CYP2D6MAPT | |
| SCHEMBL6121805 | 0.74 | TTR (0.57) | IDO1MEN1USP2CYP3A4CYP2D6 | |
| SCHEMBL333943 | 0.73 | CA3 (0.41) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL25357651 | 0.72 | CA3 (0.46) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL31114606 | 0.72 | CA3 (0.46) | CA3CA6CA5ACA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118515534-B | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-11-05 | — | — | CN | claimed |
| CN-118515534-A | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-08-20 | — | — | CN | claimed |
| US-12503445-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2025-12-23 | — | — | US | disclosed |
| CN-120077035-A | As CX32,4, 6-Trisubstituted 1,3, 5-triazines as modulators of CR1 | 阿斯利康(瑞典)有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119968369-A | Cytotoxic imidazo [1,2-a ] pyridine compounds and their use in therapy | 迈里克斯制药有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20240383862-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-11-21 | — | — | US | disclosed |
| CN-118515534-B | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-11-05 | — | — | CN | disclosed |
| CN-118871440-A | 3-Substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degrading agents | 奥瑞基尼肿瘤有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118515534-A | Multi-tooth ligand, multi-tooth ligand metal catalyst, and preparation method and application thereof | 华南理工大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-117580826-A | NLRP3 inflammation corpuscle inhibitor | 阿斯利康(瑞典)有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| CN-115417856-A | Pharmaceutical application of substituted heteroaraliphthalazine derivatives and preparation method thereof | 成都奥睿药业有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| US-20130053407-A1 | PYRROLO [3,2-D] PYRIMIDIN-3-YL DERIVATIVES USED AS ACTIVATORS OF AMPK | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | US | disclosed |
| EP-2265583-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-10-12 | — | — | EP | disclosed |
| EP-2265583-A1 | SPIROINDOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-7723372-B2 | Spiroindolinone derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-05-25 | — | — | US | disclosed |
| WO-2009115425-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239889-A1 | Spiroindolinone Derivatives | LIU JIN-JUN | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343838-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CA3 3397/4885CA6 3264/4885CA5A 2764/4885 |
| US-11090304-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | CA3 3397/4885CA6 3264/4885CA5A 2764/4885 |
| US-20240383862-A1 | COMPOUNDS AND THEIR USE | NLRP3, PYCARD, NLRP1 | CA3 4547/4885CA6 4686/4885CA5A 3114/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CA3 3397/4885CA6 3264/4885CA5A 2764/4885 |
| US-20090239889-A1 | Spiroindolinone Derivatives | CCNY, RB1, NQO1 | CA3 4292/4885CA6 4172/4885CA5A 1186/4885 |
| US-12503445-B2 | Compounds and their use | NLRP3, PYCARD, NLRP1 | CA3 4547/4885CA6 4686/4885CA5A 3114/4885 |
| US-20130053407-A1 | PYRROLO [3,2-D] PYRIMIDIN-3-YL DERIVATIVES USED AS ACTIVATORS OF AMPK | PRKAG2, PRKAB2, PRKAG3 | CA3 4791/4885CA6 4717/4885CA5A 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.